MSH6 BLOCKING PEPTIDE-BLOCKING PEPTIDE
- Known as:
- MSH6 BLOCKING PEPTIDE-BLOCKING PEPTIDE
- Catalog number:
- BLP048
- Product Quantity:
- 50 |g
- Category:
- -
- Supplier:
- AbD
- Gene target:
- MSH6 BLOCKING PEPTIDE-BLOCKING PEPTIDE
Related genes to: MSH6 BLOCKING PEPTIDE-BLOCKING PEPTIDE
- Gene:
- MSH6 NIH gene
- Name:
- mutS homolog 6
- Previous symbol:
- GTBP
- Synonyms:
- -
- Chromosome:
- 2p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-29
- Date modifiied:
- 2019-04-23
Related products to: MSH6 BLOCKING PEPTIDE-BLOCKING PEPTIDE
Related articles to: MSH6 BLOCKING PEPTIDE-BLOCKING PEPTIDE
- Multiple germline variants are associated with prostate cancer (PCa) susceptibility and aggressive features; however, their value for predicting prostate cancer-specific mortality (PCSM) at the time of diagnosis remains uncertain, particularly among men with clinically localized disease. - Source: PubMed
Publication date: 2026/08/04
Lu LucyXu JulianShi ZhuqingEngelmann ValentinaTran HuyWei JunAshworth AnnabelleCornell BrandonPieczonka ChristopherIsaacs William BZheng S LillyHelfand Brian TLuo JunXu JianfengLu Jim - All individuals with colorectal cancer (CRC) should undergo genetic cancer risk assessment given its implications for personalized treatment, surveillance, risk-reduction strategies, and cascade testing. Universal screening using immunohistochemistry (IHC) for mismatch repair (MMR) proteins in tumor tissue, when combined with clinical criteria, is essential for identifying individuals at higher risk for carrying germline pathogenic variants (PVs) in resource limited countries. - Source: PubMed
Publication date: 2026/08/04
Rodríguez-Olivares José LuisAguilar-Y-Méndez DioneKimball Tamara NRivero-García PamelaRios-Valencia JavierSantuario-Facio SandraRojas-Martinez AugustoOrtiz-López RocíoBarraza-Arellano Angélica LeticiaAranda-Gutierrez AlejandroArteaga-Vazquez JazmínDe-La-Mora-Molina HéctorHerzog JosefJeter Joanne MWeitzel Jeffrey NChávarri-Guerra Yanin - Upper tract urothelial carcinoma (UTUC) is a common extracolonic manifestation of Lynch syndrome (LS) characterized by mismatch repair deficiency (MMR-D) and microsatellite instability (MSI). LS detection in UTUC relies on tissue- and clinical-based screening, which can fail to detect pathogenic germline variants (PGVs). We sought to determine the prevalence and spectrum of PGVs in UTUC through universally offered germline testing. - Source: PubMed
Publication date: 2026/08/01
Spooner Jesse TrIgel Daniel ALabbate Craig VSaporito DonikaMork MaureenVilar-Sanchez EduardoJonasch EricAdibi MehradMatin Surena F - Muir-Torre syndrome (MTs) is a rare autosomal dominant disorder characterized by sebaceous neoplasms and internal malignancies, most commonly colorectal and urothelial cancers. Prostate cancer is exceptionally rare in MTs, with only thirteen cases reported to date. - Source: PubMed
Publication date: 2026/06/23
Marchand-Crety CharlesJacquin Nicolas - Early-onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before the age of 50 years, is increasing worldwide, with a similar trend emerging in China. However, the clinicopathological and mismatch repair features of EOCRC in Chinese patients remain insufficiently characterized. We retrospectively reviewed 23,414 colorectal neoplasia cases diagnosed at West China Hospital between November 2008 and June 2023. Among these, 4,159 colorectal cancer cases with complete immunohistochemical assessment of MLH1, PMS2, MSH2, and MSH6 were included in the primary analysis. Clinicopathological characteristics and mismatch repair status were compared between EOCRC and late-onset colorectal cancer (LOCRC), with additional stratification by documented family history. Multivariable logistic regression was used to evaluate the independent association between early-onset status and deficient mismatch repair (dMMR). Compared with LOCRC, EOCRC showed less favorable clinicopathological features, including higher proportions of poor differentiation, T4 tumors, nodal involvement, and advanced TNM stage. EOCRC also had a significantly higher prevalence of dMMR. In multivariable analysis, early-onset status was independently associated with dMMR in the overall cohort (adjusted OR, 2.27; 95% CI, 1.60-3.22; p < 0.001), and among patients without documented family history (adjusted OR, 1.95; 95% CI, 1.33-2.86; p < 0.001). Patterns of MMR protein loss differed according to documented family history status. In conclusion, EOCRC in this Chinese MMR-tested cohort was associated with more advanced clinicopathological features and a higher prevalence of dMMR, supporting routine MMR assessment in young patients with colorectal cancer. - Source: PubMed
Publication date: 2026/07/31
Tang DengMao ZhigangLan SiqiSong YaliChen SiChen YuemeiSu MiTang YufeiZhu ChengyiYan RuitingZhang JiWang Yufang